ABSTRACT
BACKGROUND: Malignant transformation of endometriosis is infrequent at the laparoscopic trocar site. Although malignant transformation is uncommon, it must be acknowledged in order to achieve radical resection. CASE PRESENTATION: We report on a 54-year-old woman with trocar site endometriosis 2 years after laparoscopic ovarian endometrial resection. Physical examination revealed a subcutaneous solid tumor with a diameter of 3 cm surrounding the scar of laparoscopic surgery in the right lower abdomen. Transabdominal ultrasonography showed a cystic tumor in the subcutaneous adipose layer of the right lower abdomen. The pathological diagnosis was poorly differentiated endometrioid carcinoma. Hysterectomy, bilateral salpingo-oophorectomy and pelvic lymphadenectomy were then performed. Histological examination revealed mixed endometrioid carcinoma and clear cell carcinoma. After six cycles of chemotherapy, computed tomography showed no signs of recurrence. CONCLUSIONS: Malignant transformation of laparoscopic endometriosis is very uncommon, and the diagnosis and stage are determined by clinical manifestations and imaging examination. The main therapy methods are radical surgery combined with neoadjuvant chemotherapy and adjuvant radiotherapy. At the same time, reducing iatrogenic abdominal incision implantation is an effective prevention method.
Subject(s)
Carcinoma, Endometrioid , Endometriosis , Laparoscopy , Carcinoma, Endometrioid/diagnosis , Carcinoma, Endometrioid/etiology , Carcinoma, Endometrioid/surgery , Endometriosis/diagnosis , Endometriosis/etiology , Endometriosis/surgery , Female , Humans , Hysterectomy/adverse effects , Hysterectomy/methods , Laparoscopy/adverse effects , Laparoscopy/methods , Middle Aged , Surgical Instruments/adverse effectsABSTRACT
Malignant transformation of endometriosis is rare, and most cases concern the ovaries, while extraovarian cases are mostly found in the rectovaginal septum. Incisional adenocarcinoma is extremely rare, with only few cases reported in the literature, while their molecular profile remains unknown. Thus, we report on an abdominal wall cesarean section scar endometrioid adenocarcinoma studied by next-generation sequencing and microsatellite instability analysis.
Subject(s)
Abdominal Neoplasms/pathology , Abdominal Wall/pathology , Biomarkers, Tumor/metabolism , Carcinoma, Endometrioid/pathology , Cesarean Section , Cicatrix/pathology , Postoperative Complications/pathology , Abdominal Neoplasms/diagnosis , Abdominal Neoplasms/etiology , Abdominal Neoplasms/metabolism , Carcinoma, Endometrioid/diagnosis , Carcinoma, Endometrioid/etiology , Carcinoma, Endometrioid/metabolism , Female , Humans , Immunohistochemistry , Middle Aged , Postoperative Complications/diagnosis , Postoperative Complications/etiology , Postoperative Complications/metabolismABSTRACT
BACKGROUND: Endometriosis can potentially lead to the development of a malignant tumor. Most malignant tumors arising from the endometriosis originate from the ovarian endometrioma, whereas those arising from extragonadal lesions are rare. We report a rare case of endometrioid carcinoma that developed from deep infiltrating endometriosis in the uterosacral ligament 6 years after treatment for atypical proliferative endometrioid tumor of the ovary in a 48-year-old woman. CASE PRESENTATION: Six years ago, the patient underwent laparoscopic bilateral salpingo-oophorectomy for her right ovarian tumor with atypical proliferative (borderline) endometrioid tumor accompanied by ovarian endometrioma. The solid tumor in the cul-de-sac was detected during follow-up using magnetic resonance imaging. Positron emission tomography/computed tomography revealed an abnormal accumulation of 18F-fluorodeoxyglucose at the tumor site. Thus, tumor recurrence with borderline malignancy was suspected. The patient underwent diagnostic laparoscopy followed by hysterectomy and partial omentectomy. Retroperitoneal pelvic lymphadenectomy and para-aortic lymphadenectomy were also performed. The cul-de-sac tumor at the left uterosacral ligament was microscopically diagnosed as invasive endometrioid carcinoma arising from deep infiltrating endometriosis. The final diagnosis was primary stage IIB peritoneal carcinoma. The patient received six courses of monthly paclitaxel and carboplatin as adjuvant chemotherapy. The patient showed no evidence of recurrence for 2 years after the treatments. CONCLUSION: This study reports a rare case of metachronous endometriosis-related malignancy that developed 6 years after treatment for borderline ovarian tumor. If endometriosis lesions remain after bilateral salpingo-oophorectomy, the physician should keep the malignant nature of endometriosis in mind.
Subject(s)
Carcinoma, Endometrioid , Endometriosis , Ovarian Neoplasms , Carcinoma, Endometrioid/etiology , Carcinoma, Endometrioid/surgery , Endometriosis/surgery , Female , Humans , Ligaments , Middle Aged , Neoplasm Recurrence, Local , Ovarian Neoplasms/etiology , Ovarian Neoplasms/surgery , Prognosis , Salpingo-oophorectomyABSTRACT
BACKGROUND: Prognosis of the course of tumor progression is one of urgent problems of clinical oncology. A relevant specificity of endometrial cancer is its clinical polymorphism within the same histological type of the disease. The search for molecular-biological features associated with the aggressive phenotype of endometrioid carcinomas is indisputably urgent. AIM: To study molecular-biological features of endometrioid carcinoma of the endometrium (ECE) and to identify the molecular subtype of tumors with high potential of malignancy. MATERIALS AND METHODS: Surgical specimens of 127 patients with EC, stages I-II, aged 36-72 (the average age - 59.3 ± 3.2) were studied using morphological and immunohistochemical methods. The multivariant analysis with the Kullback's informative measure and PanelomiX were used to estimate the significance of the expression of specific biomarkers. RESULTS: The expression of a complex of multifunctional markers was evaluated in ECE cells of different malignancy stage: p53, FOXP3, p21WAF1/CIP1, Ñ16INK4a, E2F1, cyclins Ð and D1, Her2/neu, Ñ-Myc, Ð-cadherin, ß-catenin, vimentin, CD44, CD24. A triad of biomarkers with threshold expression levels was determined (Ñ53 < 45%; FOXP3 > 14%; Ñ-Myc < 10%). The high expression of oncogene c-Myc and oncosuppressor p53 along with the low level of FOXP3 in tumor cells of ECE was associated with high proliferative potential, low differentiation grade, and deep invasion of a tumor into the myometrium. CONCLUSIONS: The molecular phenotype of ECE, most informative in terms of specificity and sensitivity (95%) - Ñ5highFOXP3lowc-Mychigh, was first characterized, which would help identify a high-grade subtype of this cancer form.
Subject(s)
Biomarkers, Tumor , Carcinoma, Endometrioid/etiology , Carcinoma, Endometrioid/pathology , Endometrial Neoplasms/etiology , Endometrial Neoplasms/pathology , Disease Susceptibility , Female , Gene Expression , Humans , Immunohistochemistry , Middle Aged , Neoplasm Grading , Neoplasm StagingABSTRACT
OBJECTIVES: Mismatch repair deficiency is observed in 25%-30% of all endometrial cancers. This can be detected by the absence of mismatch repair protein staining on immunohistochemistry, and is used as a screen for Lynch syndrome. Only 10% of women with mismatch repair deficiency have Lynch syndrome, but mismatch repair deficiency may still have prognostic significance. The objective of this study was to compare clinical outcomes between mismatch repair-deficient and mismatch repair-proficient low-risk endometrioid endometrial cancers (stage IA, grade 1 or 2). METHODS: This was a retrospective population-based cohort study of all low-risk endometrioid endometrial cancers (stage IA, grade 1 or 2) from the Vancouver Coastal Health Authority region from February 2011 to January 2016 that were assessed for mismatch repair deficiency. Any other histology, stage, or grade was excluded from the study. Primary outcome measures were progression-free survival and overall survival calculated using Kaplan-Meier method and log-rank tests. Cox proportional hazards model estimated the association between mismatch repair deficiency and recurrence and death after adjustment for covariates, expressed as hazard ratios (HRs). Secondary outcome measures were recurrence rates expressed per 100 person-years (p100py). RESULTS: There were 475 patients diagnosed with low-risk endometrioid endometrial cancer, including 131 with mismatch repair-deficient (27.6%) and 344 with mismatch repair-proficient (72.4%) tumors. Women with mismatch repair-deficient tumors had worse progression-free survival (24 months; p=0.0082) and higher recurrence rates (3.56 p100py) compared with those with mismatch repair-proficient tumors (27 months; 1.21 p100py, p=0.04). The absolute number of recurrences was overall low. There were 11 recurrences out of 131 mismatch repair-deficient cases (8.4%) and 14 out of 344 mismatch repair proficient cases (4.1%). After adjustment for age, lymphovascular space invasion status, adjuvant therapy, and post-operative grade, mismatch repair-deficient status remained associated with a higher risk of recurrence (HR 3.56, 95% CI 2.01 to 5.95). There was no significant difference in overall survival between mismatch repair groups (mismatch repair-proficient group 27.5 months vs 25.0 months in the deficient group) (HR 1.23, 95% CI 0.49 to 3.10). CONCLUSION: In low-risk stage IA grade 1 or 2 endometrioid endometrial cancers, mismatch repair deficiency is associated with a higher recurrence rate than mismatch repair proficiency after adjustment for covariates, implying that mismatch repair deficiency reflects a different biology in endometrial cancer.
Subject(s)
Carcinoma, Endometrioid/etiology , DNA Mismatch Repair , Neoplasms/etiology , Aged , British Columbia/epidemiology , Carcinoma, Endometrioid/mortality , Female , Humans , Middle Aged , Neoplasms/mortality , Prognosis , Retrospective StudiesABSTRACT
OBJECTIVE: Endometriosis-associated epithelial ovarian cancer (EOC) is a specific category of EOC, containing either endometrioid or clear cell carcinoma subtype. The characteristic of endometriosis-associated EOC includes an early stage at the diagnosis, presence of single histology type, and better prognosis. The synchronous two subtypes of endometriosis-associated EOC and presentation of far-advanced stage status at the initial diagnosis is rarely reported. CASE REPORT: We reported a 60-year-old postmenopausal woman with FIGO IA endometriosis-associated endometrioid carcinoma at right ovary and FIGO IVA endometriosis-associated clear cell carcinoma at left ovary, right tube, omentum, lymph node and cytology of pleural effusion and ascites treated with optimal debulking surgery and dose-intensity taxane/platinum based chemotherapy. CONCLUSION: This case report confirms the long-term concept that clear cell carcinoma has much more aggressive behavior than endometrioid cell carcinoma does, regardless of association of endometriosis or not.
Subject(s)
Adenocarcinoma, Clear Cell/pathology , Carcinoma, Endometrioid/pathology , Carcinoma, Ovarian Epithelial/pathology , Neoplasms, Multiple Primary/pathology , Ovarian Neoplasms/pathology , Adenocarcinoma, Clear Cell/etiology , Carcinoma, Endometrioid/etiology , Carcinoma, Ovarian Epithelial/etiology , Endometriosis/complications , Endometriosis/pathology , Female , Humans , Middle Aged , Neoplasms, Multiple Primary/etiology , Ovarian Neoplasms/etiology , Ovary/pathologyABSTRACT
Endometriosis is an estrogen-dependent disease, which affects 10% of women in the reproductive age. Malignant transformation is an uncommon event, which affects approximately 0.7-2.5% of women, and, when it occurs, it involves ovarian and extraovarian sites in 75% and 25% of the cases, respectively. Endometriosis correlates with presentation of clear cell and endometrioid carcinoma of the ovary. Activation of phosphatidylinositol 3-kinase (PIK3) - protein kinase B (AKT) - mammalian target of rapamycin (mTOR) pathway, aberrant chromatin remodeling due to AT-rich interactive domain-containing protein 1A (ARID1A) mutation and inactivation of estrogen receptor-α signaling seem to play a major role in the carcinogenesis. To date, little data are available regarding endometriosis-associated extraovarian malignancies. The aim of the present study was to review the clinical, pathological and prognostic features of endometriosis-related neoplasms arising from extraovarian sites, with particular focus on intestinal malignancies, urinary tract malignancies and tumors arising from surgical scars.
Subject(s)
Carcinoma, Endometrioid/diagnosis , Carcinoma, Endometrioid/etiology , Cell Transformation, Neoplastic , Endometriosis/complications , Endometriosis/pathology , Biopsy , Carcinoma, Endometrioid/therapy , Case-Control Studies , Disease Progression , Endometriosis/etiology , Endometriosis/metabolism , Female , Humans , Immunohistochemistry , Neoplasm Grading , Neoplasm Staging , PathologistsABSTRACT
AIM: Endometriosis mostly affects the ovary but can also be present outside of the ovary including the pelvic peritoneum, intestine, urinary tract and lung. In case of ovarian endometriotic cyst, an increased risk of ovarian cancer, especially of clear cell and endometrioid histology, has been reported. However, because of the rarity, cancer occurrence from endometriosis at less common sites/rare sites is poorly understood. METHODS: We conducted a nationwide survey on the less common/rare site endometriosis in 3539 authorized facilities in Japan. We requested to complete a case report form for each case, including information on the history of endometriosis, treatment for endometriosis, type of surgery, involved site(s) of cancer and endometriosis, histology of cancer, chemotherapy and outcome. RESULTS: Out of 1397 confirmed cases of less common/rare site endometriosis, 11 cases of rare site endometriosis-associated cancer (RSEAC) were reported: seven of them were associated with intestinal endometriosis, three were associated with urinary tract endometriosis and one was associated with umbilical endometriosis. Interestingly, the histology was endometrioid in seven (64%) cases, and serous, seromucinous borderline, clear cell and mucinous in one case each (10%), differing from the case of ovarian endometriosis-associated cancer, in which clear cell carcinoma are more common. CONCLUSION: Our nationwide survey on RSEAC has revealed that: (i) the incidence of malignant transformation may be lower than ovarian endometriosis, (ii) malignant transformation from endometriosis outside the abdominal cavity may be extremely rare and (iii) the histology of RSEAC is predominantly endometrioid type, suggesting an association of a hormonal effect.
Subject(s)
Cell Transformation, Neoplastic , Endometriosis/complications , Adenocarcinoma, Clear Cell/etiology , Adult , Carcinoma, Endometrioid/etiology , Endometrial Neoplasms/etiology , Endometriosis/pathology , Female , Humans , Incidence , Japan/epidemiology , Middle Aged , Ovarian Neoplasms/etiology , Surveys and QuestionnairesABSTRACT
Atypical polypoid adenomyoma (APA) is a rare uterine lesion that commonly recurs after local excision and is occasionally associated with or anticipates the development of atypical hyperplasia or endometrioid adenocarcinoma. We report a case of a 45-year-old woman affected by APA treated with local resection.
Subject(s)
Adenomyoma , Endometrium/pathology , Uterus/pathology , Adenomyoma/complications , Adenomyoma/diagnosis , Adenomyoma/pathology , Adenomyoma/surgery , Biomarkers, Tumor , Carcinoma, Endometrioid/diagnosis , Carcinoma, Endometrioid/etiology , Carcinoma, Endometrioid/pathology , Diagnosis, Differential , Endometrial Neoplasms/diagnosis , Endometrial Neoplasms/etiology , Endometrial Neoplasms/pathology , Female , Humans , Hyperplasia/diagnosis , Hyperplasia/etiology , Hyperplasia/pathology , Immunohistochemistry , Middle Aged , Neoplasm Recurrence, Local/diagnosis , Uterine Neoplasms/diagnosis , Uterine Neoplasms/etiology , Uterine Neoplasms/pathologyABSTRACT
BACKGROUND: Endometriosis is a risk factor for ovarian cancer. Endometriosis-associated ovarian cancer (EAOC), most commonly clear cell carcinoma, is believed to develop from ovarian endometrial cysts. In this study, we reviewed published cases of EAOC considered to have developed from endometrial cysts, and focused on the observation period. METHODS: We searched for articles published since January 2000 that reported cases of ovarian cancer thought to have originated from endometrial cysts using PubMed, Web of Science, and Ichushi-Web. The period from the start of follow-up of the endometrial cyst to the diagnosis of ovarian cancer was calculated. RESULTS: Seventy-nine cases were identified from 32 articles. The median period from the diagnosis of endometrial cysts to the diagnosis of ovarian cancer was only 36 months. Approximately 75% of cases developed into cancer within 60 months and most cases developed within 120 months. CONCLUSION: Our results suggest that clinically detectable cysts subsequently diagnosed as ovarian cancer might already have contained cancer cells. Therefore, the mechanism of EAOC development needs to be re-examined and appropriate management guidelines need to be developed.
Subject(s)
Carcinoma, Endometrioid/etiology , Carcinoma, Ovarian Epithelial/etiology , Endometriosis/complications , Ovarian Cysts/complications , Ovarian Neoplasms/etiology , Adult , Carcinoma, Endometrioid/diagnosis , Carcinoma, Endometrioid/pathology , Carcinoma, Ovarian Epithelial/diagnosis , Carcinoma, Ovarian Epithelial/pathology , Endometriosis/diagnosis , Endometriosis/pathology , Female , Follow-Up Studies , Humans , Middle Aged , Ovarian Cysts/diagnosis , Ovarian Cysts/pathology , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/pathologyABSTRACT
The aim of this study was to investigate the serum levels of the A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) 5 and 8 in patients diagnosed with endometrial cancer. Our study included 41 patients diagnosed with endometrial cancer. The control group consisted of 41 patients diagnosed with benign endometrial pathology. The serum samples were centrifuged and stored at -80 °C. The serum levels of ADAMTS were significantly higher (p<.001), whereas the levels of ADAMTS 8 were significantly lower in patients diagnosed with cancer (p<.001). In addition to the presence of known factors in the aetiology of endometrial cancer, the effect of inflammatory factors and some new proteins has centred on the causes of tumourigenesis in recent years. In this sense, these proteins, called the ADAMTS, are the source of new studies.Impact StatementWhat is already known on this subject? When the recent studies about endometrial cancer are evaluated, it is seen that the effects of chronic inflammation and cytokines have gained importance in its aetiology. The A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) gene family consist of 19 proteases that play essential role in the formation of the extracellular matrix (ECM) and interact with inflammatory cytokines. These proteases and their substrates provide a wide range of functions in different tissues, including ECM remodelling, angiogenesis, fibrosis and coagulation.What the results of this study add? ADAMTS 5, which causes the degradation of the ECM with Aggrecanase activity, was found to be significantly higher in patients diagnosed with cancer and ADAMTS 8 with anti-angiogenesis activity was significantly lower in patients diagnosed with endometrial cancer.What the implications are of these findings for clinical practice and/or further research? In this study, it is understood that the effect of inflammatory mediators is remarkably important in the aetiology of endometrial cancer, as in many types of organ specific cancer.
Subject(s)
ADAMTS Proteins/blood , ADAMTS5 Protein/blood , Carcinoma, Endometrioid/blood , Carcinoma, Endometrioid/etiology , Endometrial Neoplasms/blood , Endometrial Neoplasms/etiology , Adult , Aged , Case-Control Studies , Endometrium/metabolism , Female , Humans , Middle AgedABSTRACT
Laparoscopic port site endometriosis is less common in abdominal wall endometriosis, and malignant transformation of abdominal wall endometriosis is rare. We reported a case of mixed endometrioid and clear cell carcinoma arising from port site endometriosis. The patient was a 49-year-old woman with a history of laparoscopic excision of ovarian endometrioma. Physical examination revealed a subcutaneous solid tumor around the laparoscopic surgical scar. Imaging showed a suspicious malignancy. She underwent radical marginal resection of the abdominal wall tumor, flap reconstruction of the abdominal wall, hysterectomy, bilateral salpingo-oophorectomy and omental biopsy. Histological examination revealed mixed endometrioid and clear cell carcinoma. Computed tomography scan showed no evidence of recurrence after six cycles of chemotherapy. This is the first case of malignant transformation from laparoscopic trocar site endometriosis.
Subject(s)
Abdominal Neoplasms , Adenocarcinoma, Clear Cell , Carcinoma, Endometrioid , Cell Transformation, Neoplastic , Endometriosis , Laparoscopy/adverse effects , Ovarian Diseases , Abdominal Neoplasms/diagnosis , Abdominal Neoplasms/etiology , Abdominal Neoplasms/surgery , Adenocarcinoma, Clear Cell/diagnosis , Adenocarcinoma, Clear Cell/etiology , Adenocarcinoma, Clear Cell/surgery , Carcinoma, Endometrioid/diagnosis , Carcinoma, Endometrioid/etiology , Carcinoma, Endometrioid/surgery , Endometriosis/complications , Endometriosis/diagnosis , Endometriosis/etiology , Endometriosis/surgery , Female , Humans , Middle Aged , Ovarian Diseases/diagnosis , Ovarian Diseases/etiology , Ovarian Diseases/surgeryABSTRACT
BACKGROUND: Universal tumor testing for defective DNA mismatch repair (MMR) is recommended for all women diagnosed with endometrial cancer to identify those with underlying Lynch syndrome. However, the effectiveness of these screening methods in identifying individuals with Lynch syndrome across the population has not been well studied. The aim of this study was to evaluate outcomes of MMR immunohistochemistry (IHC), mutL homolog 1 (MLH1) methylation, and microsatellite instability (MSI) analysis among patients with endometrial cancer. METHODS: A complete systematic search of online databases (PubMed, EMBASE, MEDLINE, and the Cochrane Library) for 1990-2018 was performed. A DerSimonian-Laird random effects model meta-analysis was used to estimate the weighted prevalence of Lynch syndrome diagnoses. RESULTS: The comprehensive search produced 4400 publications. Twenty-nine peer-reviewed studies met the inclusion criteria. Patients with endometrial cancer (n = 6649) were identified, and 206 (3%) were confirmed to have Lynch syndrome through germline genetic testing after positive universal tumor molecular screening. Among 5917 patients who underwent tumor IHC, 28% had abnormal staining. Among 3140 patients who underwent MSI analysis, 31% had MSI. Among patients with endometrial cancer, the weighted prevalence of Lynch syndrome germline mutations was 15% (95% confidence interval [CI], 11%-18%) with deficient IHC staining and 19% (95% CI, 13%-26%) with a positive MSI analysis. Among 1159 patients who exhibited a loss of MLH1 staining, 143 (13.7%) were found to be MLH1 methylation-negative among those who underwent methylation testing, and 32 demonstrated a germline MLH1 mutation (2.8% of all absent MLH1 staining cases and 22.4% of all MLH1 methylation-negative cases). Forty-three percent of patients with endometrial cancer who were diagnosed with Lynch syndrome via tumor typing would have been missed by family history-based screening alone. CONCLUSIONS: Despite the widespread implementation of universal tumor testing in endometrial cancer, data regarding testing results remain limited. This study provides predictive values that will help practitioners to evaluate abnormal results in the context of Lynch syndrome and aid them in patient counseling.
Subject(s)
Carcinoma, Endometrioid/genetics , Endometrial Neoplasms/genetics , Lynch Syndrome II/diagnosis , Neoplasms, Cystic, Mucinous, and Serous/genetics , Carcinoma, Endometrioid/etiology , Carcinoma, Endometrioid/metabolism , DNA Methylation/genetics , DNA Mismatch Repair , DNA-Binding Proteins/genetics , Endometrial Neoplasms/etiology , Endometrial Neoplasms/metabolism , Female , Humans , Immunohistochemistry , Lynch Syndrome II/complications , Lynch Syndrome II/genetics , Microsatellite Instability , Middle Aged , Mismatch Repair Endonuclease PMS2/genetics , Molecular Diagnostic Techniques , MutL Protein Homolog 1/genetics , MutL Protein Homolog 1/metabolism , MutS Homolog 2 Protein/genetics , Neoplasms, Cystic, Mucinous, and Serous/etiology , Neoplasms, Cystic, Mucinous, and Serous/metabolismABSTRACT
We focused on specific molecular events during the development of endometriosis-associated ovarian endometrioid carcinoma (OEmCa) and ovarian clear cell carcinoma (OCCCa). Alterations in ß-catenin (encoded by CTNNB1) and microsatellite instability (MSI), as well as changes in the expression levels of HNF-1ß and DNA mismatch repair (MMR) proteins were investigated in 50 OEmCas and 21 OCCCas with endometriotic lesions. Mutations of CTNNB1 were identified in 28 (56%) of the 50 OEmCa cases and 26 (41.9%) of the 62 coexisting endometriosis lesions. MSI-high (H) was observed in 7 (14.6%) of the 48 OEmCa and 14 (23.3%) of the 60 coexisting endometriosis, and was significantly associated with loss of MMR protein expression, but not CTNNB1 mutations. Nonidentical CTNNB1 status between 2 different epithelial lesions within endometriosis was observed in 8 of 10 informative endometriosis cases that had adjacent OEmCa. Similar findings for MSI features were also found in 2 of 3 informative cases, suggesting that endometriotic lesions may predominantly consist of polyclonal cells. In contrast, high HNF-1ß expression was significantly associated with SLC3A1 expression, which plays a major role in HNF-1ß-triggered induction of reactive oxygen species in OCCCas, independent of abnormalities in both ß-catenin and MSI/MMR status. Finally, 4 inflammatory parameters associated with repeated hemorrhaging in endometriosis were significantly higher in endometriosis with MSI-high when compared with that with MSS, independent of both ß-catenin and HNF-1ß status. In conclusion, different molecular pathways including alterations in ß-catenin, MSI, and HNF-1ß levels may contribute to tumorigenesis in endometriosis-associated carcinoma.
Subject(s)
Carcinogenesis/metabolism , Endometriosis/complications , Ovarian Neoplasms/etiology , Ovarian Neoplasms/metabolism , Adenocarcinoma, Clear Cell/etiology , Adenocarcinoma, Clear Cell/genetics , Adenocarcinoma, Clear Cell/metabolism , Adult , Aged , Carcinogenesis/genetics , Carcinoma, Endometrioid/etiology , Carcinoma, Endometrioid/genetics , Carcinoma, Endometrioid/metabolism , Endometriosis/metabolism , Female , Hepatocyte Nuclear Factor 1-beta/genetics , Hepatocyte Nuclear Factor 1-beta/metabolism , Humans , Microsatellite Instability , Middle Aged , Ovarian Neoplasms/genetics , Young Adult , beta Catenin/genetics , beta Catenin/metabolismABSTRACT
A 52-year-old woman presented to our hospital complaining of genital bleeding and was found to have a 50-mm vaginal tumor that involved the bladder, rectum, and small bowel and extended to the left pelvic side wall. Her history included a bilateral salpingo-oophorectomy and a total abdominal hysterectomy for fibroids and endometriosis. She had been prescribed estrogen replacement therapy (1.25 mg/day) following the second surgery and continued it for 8 years. The pathology of the vaginal biopsy showed endometrioid adenocarcinoma. Total pelvic exenteration was recommended for complete resection, but she chose chemotherapy (paclitaxel 175 mg/m2 and carboplatin AUC:6). Clinical complete remission was obtained for 11 years. She had a recurrence 11 years later. She was again found to have a 5-cm vaginal tumor. Surgical excision with upper vaginectomy was performed. The tumor was resected without invasion of the bladder, rectum and small bowel. Histologic examination of the specimen confirmed clear cell carcinoma with endometriosis. Chemotherapy may be the first-line treatment that can preclude aggressive surgery for malignant transformation of extragonadal endometriosis. However, combined chemotherapy and surgery is necessary for this disease.
Subject(s)
Adenocarcinoma, Clear Cell/etiology , Antineoplastic Agents/therapeutic use , Carcinoma, Endometrioid/etiology , Endometriosis/complications , Intestinal Neoplasms/etiology , Neoplasm Recurrence, Local/etiology , Urinary Bladder Neoplasms/etiology , Vaginal Neoplasms/etiology , Adenocarcinoma, Clear Cell/therapy , Carcinoma, Endometrioid/therapy , Endometriosis/drug therapy , Female , Humans , Intestinal Neoplasms/therapy , Middle Aged , Neoplasm Recurrence, Local/therapy , Urinary Bladder Neoplasms/therapy , Vaginal Neoplasms/therapyABSTRACT
BACKGROUND: Synchronous endometriosis has been poorly studied in women with endometrioid borderline ovarian tumors (EBOTs). The aims of this study were to compare the clinicopathological features and prognosis of EBOTs with or without endometriosis. RESULTS: Of 52 patients diagnosed with EBOTs, no death was observed and only one case had successful pregnancy during the follow-up period. Older, menopausal EBOT patients, EBOT patients with small tumors and relatively low CA125 level probably had better progression-free survival (PFS) outcomes. About 1/3 of EBOTs had concomitant endometrial lesions. Approximately 1/3 of EBOTs were associated with endometriosis. Patients were divided into two groups according to the presence or not of endometriosis in this retrospective cohort study. Patients with endometriosis-associated endometrioid borderline ovarian tumor (EAEBOT) were more likely to be younger and premenopausal. Variables such as PFS outcomes, endometrial lesions did not differ statistically between groups. However, in specific EBOT patients like parous patients, patients with CA125 ≥ 140 U/ml or patients without fertility sparing surgery, coexisting endometriosis perhaps predicted worse PFS outcomes. CONCLUSION: We considered EAEBOT as an entity similar to non-EAEBOT. Closely follow-up for some particular patients with concomitant endometriosis was necessary.
Subject(s)
Carcinoma, Endometrioid , Endometriosis , Ovarian Neoplasms , Adult , Aged , Aged, 80 and over , Carcinoma, Endometrioid/diagnosis , Carcinoma, Endometrioid/etiology , Carcinoma, Endometrioid/pathology , Disease-Free Survival , Endometriosis/complications , Endometriosis/diagnosis , Endometriosis/pathology , Female , Humans , Menopause , Middle Aged , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/etiology , Ovarian Neoplasms/pathology , Prognosis , Young AdultABSTRACT
Malignant transformation of ovarian endometriosis was first described in 1925 by Sampson; later on it has been described in extragonadal regions by few authors also. Ovarian endometrioid and clear cell carcinoma are highly associated with endometriosis. Here we present a case of malignant transformation of ovarian endometrioma into endometrioid adenocarcinoma and review the clinical and pathological features of these tumors. A 45-years old infertile woman diagnosed as a case of bilateral chocolate cyst with pelvic endometriosis underwent total hysterectomy with bilateral salpingo-oophorectomy. A solid portion was also identified in the right sided cyst, histology of which revealed a well-differentiated endometrioid adenocarcinoma grade-II with foci of squamous morules and keratin pearls. Her pre-operative CA-125 level was within normal range. Women with endometriosis should be considered at an increased risk for the development of ovarian cancer even with normal CA-125 level.
Subject(s)
Adenocarcinoma , Carcinoma, Endometrioid , Endometriosis , Ovarian Neoplasms , Adenocarcinoma/diagnosis , Adenocarcinoma/etiology , Adenocarcinoma/surgery , Carcinoma, Endometrioid/diagnosis , Carcinoma, Endometrioid/etiology , Carcinoma, Endometrioid/surgery , Cell Transformation, Neoplastic , Endometriosis/complications , Female , Humans , Hysterectomy , Middle Aged , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/etiology , Ovarian Neoplasms/surgeryABSTRACT
In women with endometriosis, the lifetime risk of ovarian cancer is increased from 1.4% to about 1.9%. The risk of clear cell and endometrioid ovarian cancer is, respectively, tripled and doubled. Atypical endometriosis, observed in 1-3% of endometriomas excised in premenopausal women, is the intermediate precursor lesion linking typical endometriosis and clear cell/endometrioid tumors. Prolonged oral contraceptive use is associated with a major reduction in ovarian cancer risk among women with endometriosis. Surveillance ± progestogen treatment or surgery should be discussed in perimenopausal women with small, typical endometriomas. In most perimenopausal women with a history of endometriosis but without endometriomas, surveillance instead of risk-reducing bilateral salpingo-oophorectomy seems advisable. Risk-reducing salpingo-oophorectomy might benefit patients at particularly increased risk, but the evidence is inconclusive. Risk profiling models and decision aids may assist patients in their choice. Screening of the general perimenopausal population to detect asymptomatic endometriomas is unlikely to reduce disease-specific mortality.